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11 indirect comparisons). All the results were obtained from
indirect comparison. Dutasteride, compared to ﬁnasteride, sig-
niﬁcantly improved AUA-SI score (WMD = 1.53), and inﬂuenced
PSA concentration (WMD = −1.33). Average costs (including
drugs costs, complications and prostatic cancer treatment) and
effects (LY with no surgery/prostatic cancer) were per patient:
dutasteride 5655 PLN/6.23 LY; ﬁnasteride 6081 PLN/5.13 LY.
Dutasteride was dominant therapy compared with ﬁnasteride
(more effective and less costly). CONCLUSIONS: Dutasteride is
clinically more effective and more cost-effective in BPH com-
pared to both placebo and ﬁnasteride.
PIH6
ECONOMIC EVALUATION OF CARBETOCINE FOR THE
PREVENTION OF UTERINE ATONY IN PATIENTS WITH RISK
FACTORS IN MEXICO
Del Angel-García G1, Garcia-Contreras F2, Constantino-Casas P2,
Nevarez-Sida A2, Lopez-Gonzalez N3, García-Constantino M1,
Zuñiga M3
1Instituto Mexicano del Seguro Social, México City, Mexico City,
Mexico, 2Mexican Institute of Social Security, México, Distrito Federal,
Mexico, 3Mexican Institute of Social Security, México City, Mexico
City, Mexico
OBJECTIVE: To evaluate the cost-effectiveness of IMSS formu-
lary drugs for preventing uterine atony in patients with risk
factors. METHODS: A ﬁnal report of a randomized pragmatic
clinical trial at the Mexican Institute of Social Security (IMSS) is
presented. Carbetocine and oxytocin are the only drugs within
IMSS formulary for preventing uterine atony. Risk factor
included fetal macrosomia, polyhydramnios, low insertion of the
placenta, multiple gestation, prolonged labor, uterine myomas
and chorioamnionitis. The effectiveness was deﬁned as the reduc-
tion of the number of patients with uterine atony. The use of
resources was obtained from the clinical trial and the costs were
gotten from ﬁnancial information from IMSS, and are expressed
in US 2006 dollars. Squared ji and U de Mann Whitney test were
used. Univariate and probabilistic sensitivity analyses, a Monte
Carlo microsimulation with 10,000 iterations was performed
using probability distribution data from the clinical trial. A 95%
conﬁdence interval of ICER was calculated by ellipse method.
RESULTS: Seventy-seven patients received carbetocine and 75
oxytocin. Both groups had similar obstetrics and sociodemo-
graphic characteristics. Uterine atony was reported in 19% in
the oxytocin group compared to 8% in the carbetocine one (p <
0.0001). Multiple gestation was the most frequent diagnosis,
35% (p < 0.0001). Bleeding was less than 500 mL in the carbe-
tocine group and 500–1000 mL in the oxytocin one (p < 0.0001).
Mean cost per patient treated with carbetocine was $3525 vs.
$4054 for oxytocine (p < 0.0001). Mean cost-effectiveness ratio
for oxytocin was $4944, while for carbetocine $3874; ICER
showed that carbetocine was dominant. Univariate analysis sup-
ported those results. The acceptability curve and health net ben-
eﬁts showed that carbetocine group was superior independently
of WTP. CI 99% by ellipse method showed that carbetocine was
dominant in 100% of cases. CONCLUSIONS: Carbetocine was
dominant in preventing uterine atony in patients with risk
factors.
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OBJECTIVE: As part of a health technology assessment com-
paring a single-embryo-transfer (SET) in In-Vitro Fertilization
(IVF) with the traditional double-embryo-transfer (DET) used
today in Denmark the cost-effectiveness of SET was compared
with DET. The aim was to inform decision-makers about the eco-
nomic consequences of the eventual adoption of a SET policy in
Denmark. METHODS: The analysis was based on prospective
collection of resource use and costs of singletons and twins. A
total of 213 pregnant women at the fertility clinic have been
reporting resource use (health care and so-cial sector), and days
absent from work in cost diaries during a year (from pregnancy
scan to until three months after delivery). Clinical effectiveness
data of SET and DET came from a Scandinavian multi-center
trial, and a recent Cochrane review. RESULTS: The advantage
of SET is delivery of few expensive twins compared with DET
(25%). The cost-effectiveness per clinical pregnancy of DET
(DKK 115,321 per clinical pregnancy and DKK 120,934 per
delivery) was lower than using that of SET (DKK 131,446 per
clinical pregnancy and DKK 149,833 per delivery). The cost-
effectiveness of DET is explained by a higher clinical pregnancy
rate, a higher rate of delivery, and more children born. However,
DET is also a more expen-sive alternative for the average patient
treated, because of higher costs for delivery and neonatal care.
The extra cost per patient using DET is around DKK 82,000 per
delivery and around DKK 50,000 per extra child born using
DET. CONCLUSION: The cost per delivery and per child born
is lower using DET compared with SER. However, the total costs
for DET is higher due to higher antenatal, delivery and neona-
tal costs, as well as production loss. A higher rate of twin deliv-
eries using DET explains this. These extra costs using the more
effective DET policy are moderate.
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Quantitative information on the management of PHN, a com-
plication of HZ, is scarce, with the most recent data from 1975.
With the imminent arrival of a prophylactic Zoster vaccine, it is
important to document the burden of PHN in the UK. OBJEC-
TIVES: To estimate the proportion of HZ patients developing
PHN, the duration, resource use and costs of PHN sufferers,
using two deﬁnitions: pain persisting one (1-month deﬁnition) or
three months (3-month deﬁnition) after HZ onset. METHODS:
Records of immuno-competent individuals of ≥50 years, diag-
nosed with HZ between 2000 and 2005, and with ≥1-year
follow-up were selected from the UK General Practice Research
Database (GPRD). PHN episodes were identiﬁed by formal diag-
nosis and prescriptions of typical neuropathic pain medications.
